Voorbeelden van het gebruik van Vitekta in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Vitekta contains lactose.
How is Vitekta used?
Vitekta, the recommended dose of.
Why is Vitekta approved?
Other information about Vitekta.
Vitekta 150 mg Outer packaging only.
Do not stop taking Vitekta.
Vitekta contains the active substance elvitegravir.
Medicines that should never be taken with Vitekta.
Vitekta should be administered once daily as follows.
Refer to the package leaflet for Vitekta 150 mg tablets.
What Vitekta looks like and contents of the pack?
Interactions requiring dose adjustment of Vitekta.
Vitekta must always be taken with certain other HIV medicines.
Please refer to the Summary of Product Characteristics for Vitekta 85 mg tablets.
No dose adjustment of Vitekta is required for patients with renal impairment.
For use of the 150 mg tablet, please refer to the Summary of Product Characteristics for Vitekta 150 mg tablets.
Vitekta stops this enzyme working
There are no data to recommend the use of Vitekta with dosing frequencies
Vitekta must be administered in combination with a ritonavir-boosted protease inhibitor.
therefore no dose adjustment of Vitekta is required.
The choice of dose of Vitekta depends on which other medicines it is given with.
Vitekta is indicated for use only when co-administered with ritonavir as a boosting agent.
After 48 weeks, around 59% of patients treated with Vitekta(207 out of 351)
Vitekta should not be used in combination with products containing elvitegravir
The use of Vitekta must be accompanied by the use of effective contraception see sections 4.4 and 4.5.
Vitekta must not be used with certain other medicines that may reduce its effectiveness
Your treatment with Vitekta should only be started by a doctor who is experienced in treating HIV infection.
Vitekta may interact with other medicines which can affect the amounts of Vitekta or other medicines in your blood.
The choice of dose of Vitekta depends on the co-administered protease inhibitor see Table 1